Harrow, Inc. Loss Contingency, Damages Sought, Value
Harrow, Inc. (HROW) reported Loss Contingency, Damages Sought, Value of $14.50 million for the 1-month period ending 2024-11-30, per its 10-Q filed 2025-11-10.
Financial Statements › Notes › Commitment and Contingencies › Loss Contingency
us-gaap:LossContingencyDamagesSoughtValue · last filed 2025-11-10
- 2024-11-30: Loss Contingency, Damages Sought, Value 1 month $14.50M.
- 2019-02-28: Loss Contingency, Damages Sought, Value 1 month $640.00K.
| Period end | Loss Contingency, Damages Sought, Value 1 month |
|---|---|
| 2024-11-30 | $14.50M 10-Q · filed 2025-11-10 |
| 2019-02-28 | $640.00K 10-Q · filed 2019-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |